Atmus Filtration Technologies (ATMU) Stock
Filtration and drug delivery specialist for pharmaceutical partners. Here's the price, business snapshot, and what's worth knowing about Atmus Filtration Technologies in September 2026.
Atmus Filtration Technologies Inc (ATMU) develops inhalation and nasal drug‑delivery systems alongside filtration and device engineering services for pharmaceutical partners. The company aims to commercialise integrated device‑and‑drug solutions that can improve therapy delivery for respiratory and nasal conditions, leveraging specialised know‑how in aerosol and filtration technology. Key investor considerations include revenue potential from licensing and partner programmes, the need for regulatory approvals for device‑drug combinations, and the practical challenges of scaling manufacturing. With a market capitalisation of about $3.67bn, Atmus sits in a specialised part of the healthcare‑equipment market where collaborations and intellectual property matter. Risks include regulatory setbacks, competition from larger device makers, and variable adoption by pharma customers. This summary is general, educational information and not personal investment advice; values can rise or fall and past performance is not a reliable indicator of future returns.
About This Stock
ATMUS FILTRATION TECHNOLOGIES INC
ATMU
Current Price
$45.39
Potential 12 Month Profit
19.44%
Sector
N/A
Industry
N/A
Ticker
ATMU
Market Cap
$3.71B
Potential 12 Month Profit
19.44%
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ATMUS stock with a target price of $53.69, indicating significant upside.
Financial Health
ATMUS Filtration Technologies is performing well with solid profits, cash flow, and revenue growth.
Dividend
ATMUS Filtration's low dividend yield of 0.48% indicates limited returns for dividend-seeking investors. If you invested $1000 you would be paid $4.80 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Growth via Partnerships
Atmus’s collaborations with pharmaceutical companies can scale revenue through licensed device‑drug pairings, though outcomes depend on regulatory success and commercial adoption.
Technology Edge
Proprietary inhalation and filtration technologies may differentiate offerings and attract deals, but R&D and regulatory risk mean results are uncertain.
Demand Drivers
Global respiratory disease trends and ageing populations support long‑term demand for delivery devices, although competition and reimbursement pressures remain considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.